Antimicrobial Peptides in Periodontitis

Periodontal Disease : Chronic Periodontitis Clinical Trial

— PAROPAM  

Official title:

Antimicrobial Peptides in Periodontitis : a Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02793453
• Other study ID #: PO15100
• Status: Completed
• Phase: N/A
• First received: May 27, 2016
• Last updated: March 29, 2017
• Start date: January 19, 2016
• Est. completion date: April 2016

Study information

• Verified date: March 2017
• Source: CHU de Reims
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Periodontal diseases are complex chronic pathologies presenting a high prevalence worldwide. Etiopathological process involved in initiation and progression of these multifactorial diseases are not well understood, explaining the huge clinical forms variability and the complexity of the currently used classification of periodontal diseases. Recently, the implication of antimicrobial peptides (AMPs) have been suggested as potential track of explanation for periodontal diseases pathogeny. The here presented study explore the level of expression of genes coding those peptides by studying periodontal smears obtained from healthy and periodontitis patients.

Description:

This study explore the level of expression of genes coding those peptides by studying Messenger RNA (mRNA) purified from periodontal smears obtained from healthy and periodontitis patients by "Masterpure©" protocol.After reverse transcription (RT-PCR), in-silico design of primers and specificity and efficiency calculation, Complementary DNA (cDNA) are quantified by a semi-quantitative method (delta-delta CT) vs a Housekeeping gene. Wilcoxon-Mann & Whitney tests and Chi² tests are performed to check the significativity of the results between groups.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: April 2016
• Est. primary completion date: March 23, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients suffering of moderate to severe chronic periodontitis as described by the classification Armitage-1999, aged 35-65yo

Exclusion Criteria:

• Pregnant females, patients suffered from any other systemic diseases (cardiovascular, pulmonary, liver, cerebral, diseases or diabetes, cancer)

• patients that had received antibiotic treatment in the previous 3 months or who were taking long-term anti-inflammatory drugs; who had received a course of periodontal treatment or orthodontics treatment within the last 6 months; who were heavy smokers (>5 cig/day)

Related Conditions & MeSH terms

• Chronic Periodontitis
• Gingival Diseases
• Periodontal Disease : Chronic Periodontitis
• Periodontal Diseases
• Periodontitis

Intervention

Other:
• periodontal smears

Locations

Country	Name	City	State
France	Chu de Reims	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antimicrobial peptides expression levels	Level of expression of antimicrobial peptides assessed by RT-PCR	Day 0
Secondary	mRNA quantity	Quantity of mRNA purified on the smears	Day 0